SOURCE: Patheon


October 20, 2014 12:45 ET

Patheon® Regulatory Expert Selected by French Agency to Present at 2014 PIC/S Annual Seminar

DURHAM, NC--(Marketwired - October 20, 2014) - Katherine Grioteir, a leading regulatory expert at Patheon, the pharmaceutical services business owned by DPx Holdings B.V., was selected by the French Agency to be one of two industry speakers at the 2014 PIC/S Annual Seminar on Wednesday, Oct. 22, through Friday, Oct. 24, in Paris, focusing on the topic of dedicated facilities in the CDMO industry.

Griotier will present a case study highlighting Patheon's expertise in handling high potency compounds at its recently built facility in Bourgoin, France. Patheon's Bourgoin site specializes in solid oral dosage forms, including Investigational Medicine Products. In 2010, the site near Bourgoin began an innovative approach to handling highly potent compounds in its product development services suite. As part of its industrial strategy, the site is growing capabilities in innovative fields relating to the handling of potent compounds.

Griotier's presentation will showcase Patheon's strategic plan for manufacturing selective cytostatic tablets at the Bourgoin multiproduct facility and highlight key elements supporting substantial changes in manufacturer's licensing due to changes in domestic regulation classification.

The PIC/S Annual Seminar is hosted by France and the National Security Agency of Medicines and Health Products. Approximately 120 PIC/S inspectors from 46 participating countries including the United States, Canada, Japan, as well as partners from European Medicines Agency and the World Health Organization will be in attendance. For more information, contact the Seminar Secretariat at

About DPx Holdings B.V.
DPx Holdings B.V. is the privately held parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. DPx Holdings B.V. was founded in 2014 as a result of the merger of Patheon and DSM Pharmaceutical Products and is owned 51% by JLL Partners and 49% by Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. DPx Holdings B.V. offers customers unsurpassed quality, end-to-end services and value through its three business units. For more information, visit

About Patheon®
Patheon® is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms, including small molecule API and biologic drug substances. Patheon, a business unit of DPx Holdings B.V., encompasses the combined commercial manufacturing capabilities and pharmaceutical product development services, as well as offers a full array of biologic services and pharmaceutical active pharmaceutical ingredients (API) development. Patheon is #1 in product development services, #2 in commercial scale product manufacturing and is #1 in quality. For more information, visit

Contact Information